<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140746</url>
  </required_header>
  <id_info>
    <org_study_id>PET-NAC-GC</org_study_id>
    <nct_id>NCT05140746</nct_id>
  </id_info>
  <brief_title>Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer</brief_title>
  <official_title>A Prospective Study on Predicting the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to explore the value of 68Ga-FAPI-04 and 18F-FDG PET/CT in the evaluation&#xD;
      of treatment response to neoadjuvant chemotherapy(NAC) for patients with locally advanced&#xD;
      gastric cancer(LAGC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the start of NAC, baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans will be&#xD;
      scheduled in all enrolled patients. Next, the patients with resectable LAGC will receive NAC&#xD;
      treatment, surgery will follow 3~6 weeks after finishing NAC. Abdomen 68Ga-FAPI-04 PET/CT and&#xD;
      18F-FDG PET/CT will be scheduled after one cycle of NAC treatment or before surgery. Imaging&#xD;
      response measurements will be compared with the histopathological tumor regression grade&#xD;
      (TRG) of the resection specimen as gold standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">September 10, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction for NAC efficacy</measure>
    <time_frame>Two weeks after surgery</time_frame>
    <description>Predictive value of 68Ga-FAPI PET/CT and 18F-FDG PET/CT for LAGC in NAC response assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized uptake value(SUV)</measure>
    <time_frame>Two weeks after surgery</time_frame>
    <description>SUV of 68Ga-FAPI and 18F-FDG uptake on PET/CT images for primary gastric cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target-to-background ratio(TBR)</measure>
    <time_frame>Two weeks after surgery</time_frame>
    <description>68Ga-FAPI and 18F-FDG uptake ratio of primary gastric cancer to mediastinum blood pool on PET/CT images.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic efficacy for metastatic lymph nodes</measure>
    <time_frame>Two weeks after surgery</time_frame>
    <description>The sensitivity, specificity, NPV, PPV and accuracy of 68Ga-FAPI PET/CT for metastatic lymph nodes in comparison with those of 18F-FDG PET/CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>PET/CT for prediction of NAC efficacy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT will be scanned before, during or after NAC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT</intervention_name>
    <description>Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.</description>
    <arm_group_label>PET/CT for prediction of NAC efficacy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Age between 18-75 years.&#xD;
&#xD;
          2. Histologically confirmed gastric adenocarcinoma through gastroscopy.&#xD;
&#xD;
          3. Resectable gastric cancer.&#xD;
&#xD;
          4. ECOG performance status 0-1.&#xD;
&#xD;
          5. White blood count &gt;4x109/L, Absolute neutrophil count (ANC) &gt;2x109/L, Hemoglobin&#xD;
             (Hb)&gt;90g/L, Platelets &gt;100x109/L.&#xD;
&#xD;
          6. Ejection Fraction&gt;50%.&#xD;
&#xD;
          7. Serum bilirubin &lt;1.5x ULN; ALT and AST &lt;1.5x ULN.&#xD;
&#xD;
          8. Serum creatinine ≤1.5x ULN, or GFR&gt; 60ml/min.&#xD;
&#xD;
          9. Agreement to participate in this study with informed consent form.&#xD;
&#xD;
         10. Willingness and ability to comply with the protocol for the duration of the study.&#xD;
&#xD;
         11. No children bearing petential in the next six months before enrollment.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. With second primary malignant diseases in past five years, exceptions include basal&#xD;
             cell and squamous cell carcinoma of the skin that have been cured.&#xD;
&#xD;
          2. Known hypersensitivity reaction to chemotherapy drugs or with contraindications.&#xD;
&#xD;
          3. With severe disease or other unsuitable conditions determined by investigators.&#xD;
             Inadequate organ function.&#xD;
&#xD;
          4. With uncontrollable diabetic or fasting blood glucose level ≥11 mmol/L on the&#xD;
             test-day.&#xD;
&#xD;
          5. With severe mental symptoms, unconscious or unable to complete the examination.&#xD;
&#xD;
          6. Pregnancy or possibly pregnant woman, breastfeeding woman.&#xD;
&#xD;
          7. Lack of compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenggang Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Miao</last_name>
    <phone>0086-13671921521</phone>
    <email>myada821@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Runhua Feng</last_name>
      <phone>0086-13611920056</phone>
      <email>frh10960@rjh.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhenggang Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

